Therefore, in this review, we aimed to summarize recent advancements that have been reported on PPAR-related genes and target drugs, thereby promoting the molecular mechanism of action of NAFLD (Figure 1). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.